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OBJECTIVE—Glycosylated hemoglobin (HbA1c) recently has been recommended for the
diagnosis of diabetes by the American Diabetes Association, but its value in the prediction of
type 2 diabetes is poorly understood. In this study we evaluated how high-normal HbA1c levels
predict type 2 diabetes.
RESEARCH DESIGN AND METHODS—We measured HbA1c in 919 Caucasian sub-
jects, aged 40–79 years, and recorded new cases of type 2 diabetes in the following 15 years.
Diabetes was diagnosed with HbA1c.
RESULTS—SubjectswerestratiﬁedaccordingtobaselineHbA1c(,5.0,5.00–5.49[reference],
5.50–5.99, and 6.00–6.49%). Sex- and age-adjusted hazard ratios (95% CI) for type 2 diabetes
were 1.11 (0.30–4.41), 1.00, 3.79 (1.79–8.06), and 12.50 (5.51–28.34), respectively. Results
didnotchangeafteradjustingforseveralputativeconfoundingfactorsandwereconﬁrmedwhen
models with updated variables were used.
CONCLUSIONS—HbA1c is an independent risk factor for type 2 diabetes. Subjects with
high-normal levels of HbA1c deserve particular attention because they have a strong risk of
developing diabetes.
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G
lycosylated hemoglobin (HbA1c)
was proposed as a reliable tool for
diagnosingdiabetesandidentifying
subjects at increased risk of type 2 diabe-
tes (1). In 2010, the American Diabetes
Association (ADA) pointed out that pre-
vention strategies should be particularly
intensive in subjects with high-normal
HbA1c because they have the greatest
risk (2), but this recommendation was
based more on common sense than litera-
ture data. In fact, only few studies (3,4)
showed an elevated risk of type 2 diabetes
insubjectswithhigh-normalHbA1c.More-
over, in these studies type 2 diabetes was
self-reported during telephone interviews.
To support ADA recommendations, we
evaluated diabetes risk in the 6.00–6.49%
category of HbA1c,w i t ham o r er o b u s t
approach based on laboratory measure-
ment of glycemic parameters.
RESEARCH DESIGN AND
METHODS—The study was conducted
within the framework of the Bruneck
Study, a long-term, prospective population-
basedsurvey of atherosclerosis and its risk
factors carried out in Bruneck (northeast-
ern Italy), with a baseline evaluation in
1990 (5). Among 1,000 randomly sam-
pled Caucasian men and women aged
40–79 years, 936 volunteered. After ex-
cluding the few individuals with incom-
plete data, those with diabetes at baseline,
and the very few lost to follow-up, in the
remaining 842subjectsnew casesoftype2
diabetes were registered in the follow-up
examinations of 1995, 2000, and 2005.
The protocol was approved by the ethics
committee of the University of Verona. All
participants gave an informed consent.
Clinical and biochemical
measurements
Information about medical history, drug
use, and lifestyle was collected by a ques-
tionnaire. Weight, height, waist and hip
circumferences, and blood pressure were
measured with standard techniques. At
the baseline and follow-up examinations,
venous blood was sampled in the morn-
ing after an overnight fast for laboratory
measurements, including fasting plasma
glucose (FPG) and HbA1c (Diabetes Con-
trol and Complications Trial–aligned
assay; equipment and reagents from Bio-
Rad, Milan, Italy, at both baseline and
follow-up examinations). At both baseline
and follow-up, diabetes was diagnosed
whenHbA1cwas$6.5%ordiabetes treat-
ment was ongoing. In a parallel analysis,
diabetes was diagnosed when FPG was
$7.0 mmol/L or diabetes treatment was
ongoing. Details on parameters examined
and analytical procedures were previously
reported (5,6).
Statistical analysis
Subjects were stratiﬁed into four HbA1c
categories (,5.0, 5.00–5.49 [reference],
5.50–5.99, and 6.00–6.49%). The HbA1c
category 5.00–5.49% had the largest
number of participants (n = 345) and
was used as the reference. Hazard ratios
(HRs) for type 2 diabetes in the HbA1c
categories were estimated with Cox pro-
portional hazards models. Model 0 was
unadjusted. Model 1 included age and
sex. Model 2 also included LDL and
HDL cholesterol,log-transformed triglyc-
e r i d e s ,B M I ,w a i s t - t o - h i pr a t i o ,h y p e r -
tension, family history of diabetes,
education, alcohol, physical activity, and
smoking. Model 3 included the variables
in model 2 plus variables that are abnor-
mal in conditions potentially affecting
HbA1c (white blood cell count, hemoglo-
bin, ferritin, and creatinine). Additional
models were run with updated variables
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BRIEF REPORT(HbA1c and other variables were assessed
every 5 years during follow-up). In these
models, baseline HbA1c predicted diabe-
tes in the ﬁrst 5-year follow-up period,
HbA1c at the 5-year follow-up predicted
diabetes in the following 5-year follow-
up, and so forth in multivariable equa-
tions overcoming the limitations of single
measures. In parallel analyses, the same
m o d e l sw e r er u nw i t hi m p a i r e df a s t i n g
glucose (IFG) as a risk variable, and dia-
betes was diagnosed with FPG at baseline
and follow-up. All reported P values are
two-sided.
RESULTS—The table shows that inci-
dent cases of type 2 diabetes increased
acrosscategoriesofHbA1c:approximately
oneoffoursubjectsfromthe 6.00–6.49%
category (high normal) developed diabe-
tes over 15 years. In this category, type 2
diabetes risk was 13- to 16-fold increased
(models 0 and 1). The risk was only
slightlyreduced afteradjustingforseveral
putative confounding factors (models 2
and 3) and was deﬁnitely greater when
updated variables were included into the
models (Table 1). Analyses including
interaction terms between HbA1c catego-
ries and factors that might affect interpre-
tation of HbA1c (i.e., white blood cell
count, hemoglobin, ferritin, and creati-
nine)didnotyieldevidenceofdifferential
associations according to HbA1c level,
supportingthelackofeffectmodiﬁcation.
In parallel analyses in which diabetes
wasdiagnosedatboth baseline and follow-
up with FPG, and in which subjects at
risk were those in the IFG category, we
found that the latter conferred an in-
creased diabetes risk (HRs [95% CIs] in
subjects with IFG vs. normal FPG [,5.55
mmol/L]: 8.20 [4.66–14.40], 7.72 [4.36–
13.66], 5.83 [3.23–10.54], and 5.92
[3.24–10.80] in the four models, respec-
tively). These models included the same
v a r i a b l e sa st h o s ef o c u s i n go nH b A 1c.
However, diabetes risk in subjects with
IFG was substantially lower than in sub-
jects with high-normal HbA1c.
CONCLUSIONS—It is well known
that HbA1c captures chronichyperglycemia
in the prior 2–3 months, is well correlated
to chronic diabetes complications, and has
less preanalytical problems and biological
variability than plasma glucose, with a non-
inferior standardization (7). For such rea-
sons, HbA1c was recommended for diabetes
diagnosis and risk stratiﬁcation (1,2).
The ﬁndings of the current study
conﬁrm a progressively increased risk of
type 2 diabetesacross categories of HbA1c
and clearly document that subjects with
high-normal HbA1c have a strong risk of
developing type 2 diabetes, even after ad-
justing for several putative risk factors
(e.g., BMI) and potentially confounding
variables (e.g., anemia). Remarkably, di-
abetes risk in subjects with high-normal
HbA1cishigherthaninsubjectswithIFG.
Noteworthy,ourstudypopulationwas
entirely Caucasian, and subjects were aged
.40 years. Therefore, our ﬁndings cannot
benecessarily extrapolated to other ethnic-
ities and/or to younger subjects.
To the best of our knowledge, this
study is the ﬁrst to examine how baseline
HbA1c predicts HbA1c-diagnosed diabe-
tes. Our ﬁndings, which are consistent
withthoseofstudiesbasedonself-reported
diagnosis of diabetes (3,4), more strongly
support the ADA recommendations of us-
ing HbA1c for diabetes risk stratiﬁcation
Table 1—HRs for 15-year incidence of type 2 diabetes according to HbA1c
HbA1c category
,5.00% 5.00–5.49% 5.50–5.99% 6.00–6.49%
n 112 345 315 70
Cases of incident diabetes 3 9 31 20
Cases per 1,000 person-years 1.9 1.9 7.8 25.8
HRs (95% CIs) in models with baseline variables*
Model 0 Model 1 Model 2 Model 3
HbA1c category
,5.00% 1.00 (0.27–3.68) 1.11 (0.30–4.14) 1.18 (0.31–4.41) 1.27 (0.34–4.79)
5.00–5.49% (reference) 1.00 1.00 1.00 1.00
5.50–5.99% 4.30 (2.05–9.03) 3.79 (1.79–8.06) 3.24 (1.50–6.98) 3.21 (1.49–6.92)
6.00–6.49% 15.67 (7.13–34.47) 12.50 (5.51–28.34) 9.74 (4.21–22.56) 9.26 (4.01–21.40)
P value for trend ,0.001 ,0.001 ,0.001 ,0.001
HbA1c (per 1% increase) 11.00 (5.66–21.39) 8.54 (4.21–17.31) 6.08 (2.96–12.47) 6.05 (2.90–12.60)
HRs (95% CIs) in models with updated variables†
Model 0 Model 1 Model 2 Model 3
HbA1c category
,5.00% 2.31 (0.39–13.92) 2.55 (0.42–15.39) 2.55 (0.42–15.58) 2.43 (0.40–14.97)
5.00–5.49% (reference) 1.00 1.00 1.00 1.00
5.50–5.99 12.58 (3.83–41.30) 11.62 (3.52–38.36) 10.97 (3.30–36.47) 11.43 (3.43–38.07)
6.00–6.49% 61.05 (18.23–204.4) 52.82 (15.57–179.3) 45.52 (13.1–158.0) 46.72 (13.4–163.3)
P value for trend ,0.001 ,0.001 ,0.001 ,0.001
HbA1c (per 1% increase) 41.37 (18.79–91.07) 36.82 (16.30–83.21) 31.10 (13.31–72.7) 32.24 (13.60–76.41)
Model0wasunadjusted.Model1includedageandsex.Model2includedthevariablesinmodel1plusLDLandHDLcholesterollevels,log-transformedtriglyceridelevels,
BMI,waist-to-hipratio,hypertension,familyhistoryofdiabetes,education,alcoholuse,physicalactivityscore,andsmokingstatus.Model3includedallvariablesinmodel2
pluswhitebloodcellcount,hemoglobin,ferritin,andcreatinine.*CoxmodelsinwhichHbA1candothervariablesatbaselinewereusedtopredictdiabetesinthe15-year
follow-up. †Cox models in which updated HbA1c and other variables were used to predict diabetes in subsequent 5-year follow-up periods (see text for details).
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Bonora and Associatesand including subjects with high-normal
levels in an effective prevention strategy.
These subjects, indeed, have a high rate of
progression to diabetes and deserve partic-
ular attention in order to prevent or delay
the disease. Speciﬁc intervention trials,
however,areneededtoconﬁrmsuchacon-
clusion because those conducted so far,
b a s e do nl i f e s t y l ec h a n g e sa n d / o rd r u g
use, recruited subjects at risk according to
their plasma glucose levels and not HbA1c.
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